(Q35021331)

5 August 2017

1 reference

title

The role of systemic chemotherapy in the management of muscle-invasive bladder cancer (English)

1 reference

5 August 2017

1 reference

3

Ian F Tannock

1 reference

5 August 2017

Helen G Juffs

1

1 reference

PubMed ID

12473515

5 August 2017

Malcolm J Moore

series ordinal

2

1 reference

5 August 2017

1 December 2002

1 reference

Lancet Oncology Commission

5 August 2017

1 reference

5 August 2017

3

1 reference

5 August 2017

738-747

1 reference

5 August 2017

12

1 reference

Stat bite: U.S. urinary bladder cancer death rates

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Adjuvant chemotherapy of bladder cancer: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Adjuvant chemotherapy for high-risk urothelial transitional cell carcinoma: the Princess Margaret Hospital experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Uncertainty and outcome of invasive bladder tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Prognostic indices for bladder cancer: an analysis of patients with transitional cell carcinoma of the bladder primarily treated by radical megavoltage X-ray therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Concurrent cisplatin and radiotherapy for patients with muscle invasive bladder cancer who are not candidates for radical cystectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

The management of invasive bladder cancer: a review of selected Australasian studies in radiotherapy, chemotherapy and cystectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Muscle-invasive transitional cell carcinoma of the urinary bladder: a population-based study of patterns of care and prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Pelvic lymph node dissection can be curative in patients with node positive bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Identification of p53 gene mutations in bladder cancers and urine samples

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Accumulation of nuclear p53 and tumor progression in bladder cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Chemotherapy in the management of bladder tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A National Bladder Cancer Collaborative Group A Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide, and DDP in disseminated transitional cell carcinomas of the urinary tract

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Adriamycin versus adriamycin plus cis-diamminedichloroplatinum (DDP) in advanced transitional cell bladder carcinoma. A Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced B

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Concurrent radiation and cisplatin in the treatment of advanced bladder cancer: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Combined radiation and chemotherapy for locally advanced transitional cell carcinoma of the urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Adjuvant Chemotherapy with Doxorubicin (Adriamycin) and 5-Fluorouracil in T3, NX, MO Bladder Cancer Treated with Radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Advanced Bladder Cancer (Stages pT3b, pT4a, pN1 and pN2): Improved Survival after Radical Cystectomy and 3 Adjuvant Cycles of Chemotherapy. Results of a Controlled Prospective Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Adjuvant chemotherapy in T3 carcinoma of the bladder. A prospective trial: preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Neo-adjuvant (Pre-emptive) Cisplatin Therapy in Invasive Transitional Cell Carcinoma of the Bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Advanced Bladder Cancer Overview Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Neoadjuvant chemotherapy in bladder cancer: a randomized study. Nordic Cystectomy Trial I

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900930-0

7 January 2021

10.1016/S1470-2045(02)00930-0

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12473515